Objective: To study the specific killing effect of (131)I-labeled Herceptin on breast cancer cell lines positive for Her-2 expression.
Methods: Anti-Her-2 monoclonal antibody Herceptin was labeled with (131)I by means of IODO-GEN, and the killing effects of Herceptin on SK-BR-3, MCF-7 and A549 cell lines expressing Her-2 were evaluated with MTT assay.
Results: (131)I-Herceptin had immunoactivity had to that of Herceptin but possessed stronger killing effects on the cell lines expressing Her-2 than Herceptin and (131)I used alone (P<0.05). Its killing effect on cell lines negative or only weakly positive for Her-2 expression was similar to that of (131)I and Herceptin.
Conclusion: (131)I-Herceptin can specifically kill Her-2-positive cancer cells in vitro.